Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years or older~* Best-corrected visual acuity (BCVA) of 65 letters read or greater (Snellen equivalent of 20/50 or better) in the study eye~* HbA1c ≤ 12%, as assessed by the central laboratory~* Moderate to very severe NPDR as per ETDRS Severity Scale, based on 7 standard field stereo colour fundus photograph~* Central subfield thickness of ≤ 340µm on Spectralis SD-OCT or ≤ 320µm on non-Spectralis SD OCT in the study eye, with or without mild centre-involved diabetic macular oedema~* No evidence of total PVD in the study eye~* Written informed consent obtained from the subject prior to screening procedures~Exclusion Criteria:~* History of or current ocular condition in the study eye that may interfere with the assessment of the progression to PDR~* Presence of epiretinal membrane in the study eye~* Presence of foveal ischemia in the study eye~* Presence of pre-retinal or vitreous haemorrhage in the study eye~* Presence of iris or angle neovascularisation in the study eye~* Any active ocular / intraocular infection or inflammation in either eye~* Aphakic study eye~* Uncontrolled hypertension in the opinion of the Investigator~* Pseudoexfoliation, Marfan's syndrome, phacodonesis or any other finding in the Investigator's opinion suggesting lens / zonular instability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ocriplasmin 0.0625mg (Type: EXPERIMENTAL): None
- Ocriplasmin 0.125mg (Type: EXPERIMENTAL): None
- Sham injection (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).